Loading organizations...
§ Private Profile · London, England, United Kingdom
Women's health company providing at-home vaginal microbiome tests for individual consumers, offering personalized wellness insights.
Juno Bio, a London, UK-based organization, was founded in 2018 by co-founder and CEO Hana Janebdar and co-founder Dr. Leighton Turner, with Professor Gregory Buck serving as an advisor. Backed by Illumina, the company develops at-home tests to analyze and decode the vaginal microbiome for women's health, providing personalized wellness insights and addressing vaginal infections. Leveraging advanced microbiome research, Juno Bio built large-scale data repositories, notably through The Juno Study conducted in 2019. This comprehensive study established one of the largest vaginal microbiome repositories globally, leading to the launch of their initial Vaginal Microbiome Wellness Test. Their direct-to-consumer model focuses on empowering individual consumers with crucial health information. Its business model centers on direct-to-consumer sales of vaginal microbiome wellness tests.
Juno Bio has raised $176.0M across 1 funding round.
Juno Bio has raised $176.0M in total across 1 funding round.
Juno Bio has raised $176.0M in total across 1 funding round.
Juno Bio's investors include Alaska Permanent Fund, ARCH Venture Partners, Bezos Expeditions, Venrock.
Juno Bio has raised $176.0M across 1 funding round. Most recently, it raised $176.0M Series A in April 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 24, 2014 | $176M Series A | Alaska Permanent Fund, ARCH Venture Partners | Bezos Expeditions, Venrock | Announced |